inchiesta

(dll'inviata Elvira Terranova) - Tanti, troppi i buchi neri, ancora, a un anno di distanza dalla strage di migranti, sui soccorsi dopo il naufragio dell'imbarcazione 'Summer Love' avvenuto davanti alla spiaggia di Steccato di Cutro e provocando la morte di almeno 94 persone, tra cui 35 bambini. L'inchiesta della Procura di Crotone, guidata da Giuseppe Capoccia, va avanti. Non senza difficoltà. Anche se è già in dirittura d'arrivo.

Enterprises doing "good, but not great" when it comes to implementing digital trust, according to annual State of Digital Trust survey

TÜBINGEN, Germany, Jan. 9, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors. The infusion of fresh capital is set to boost the progress of Acousia's Kv7.4 activator programs, with a focus on advancing the ongoing clinical development of ACOU085.

L'inchiesta del quotidiano: perché l'esercito non ha reagito subito il 7 ottobre

• Gaza, miliziani: "Soldato israeliano in ostaggio ucciso in raid aereo Idf"

MONTRÉAL, Oct. 31, 2023 /PRNewswire/ -- The Law firm of Faguy & Co. today announces that the Superior Court of Québec has scheduled a hearing to be held on December 14, 2023, at 9:30 am at 1 Notre Dame Street East, Montreal, Qc., in a room to be identified, to approve the settlement among all of the parties to the class proceedings entitled Majestic Asset Management and Turn8 Partners Inc. v. The Toronto-Dominion Bank, bearing Court File No. 500-06-000914-180.

I dati del rapporto ‘Unifying Generations: Costruire un percorso di solidarietà intergenerazionale in Italia’ promosso da Edwards Lifesciences

TÜBINGEN, Germany, Oct. 9, 2023 /PRNewswire/ -- Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ACOU085 in patients with cisplatin-induced hearing loss.

LYNGE, Denmark, Sept. 5, 2023 /PRNewswire/ -- Hearing aid innovator Signia, part of WS Audiology, today launches Integrated Xperience, a breakthrough technology that enables hearing aid wearers to hear all speakers in noisy group conversations clearly. Even when speakers move or the wearer turns their head, the hearing aids ensure improved speech understanding. For a demo video on how Integrated Xperience works, please click here.